• Agnieszka Kołacińska, Justyna Chałubińska, Maria Błasińska-Morawiec, Izabela Dowgier-Witczak, Wojciech Fendler, Radzisław Kordek, and Zbigniew Morawiec.
• Department of Surgical Oncology, Cancer Centre, Copernicus Memorial Hospital, Lodz, Poland.
• Arch Med Sci. 2012 May 9; 8 (2): 310315310-5.

IntroductionPathologic complete response (pCR) after neoadjuvant systemic treatment for inoperable locally advanced breast cancer is defined as complete microscopic disappearance of invasive cancer in both the breast and axilla in the postoperative specimen. The aim of the study was to characterize the groups of younger (≤ 40 years old) and older (≥ 70 years old) breast cancer patients who achieved a pCR.Material And MethodsOne hundred thirty-eight consecutive patients aged between 30 and 78 years with locally advanced breast cancer, operated on after neoadjuvant systemic treatment between November 2007 and June 2010, were analyzed. In this group 9 women (6.5%) were 40 years of age or younger, and 12 patients (8.7%) were 70 years of age or older.ResultsIn the younger group, pCR was achieved in 1 patient with triple negative, invasive ductal breast cancer, G3, BRCA 1 mutation, treated with cisplatin. A near pCR was achieved in 2 other patients, with triple negative, invasive ductal breast cancer, G3, treated with AT. The pCR in the breast was found in a HER2 positive patient. In older patients, pCR was achieved in 2 patients with triple negative, invasive ductal breast cancer, G3, treated with AT or FEC. Pathologic complete response in the axilla was achieved in 1 patient with triple negative, ductal carcinoma. The pCR rates were significantly higher in triple negative breast cancer in both groups (p = 0.047 and p = 0.018, respectively).ConclusionsPathologic complete response was significantly associated with receptor- based subtypes in both young and old women.

4 keywords...

hide…